Regeneus (ASX:RGS)

Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human and animal health markets, with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

Board and Management

 

Dr Roger Aston
Independent Chairman

Dr Roger Aston has served on the Board since 2013 and was appointed Chairman in November 2014. He is one of the most experienced and commercially astute people in drug commercialisation in Australia.

Roger brings more than 20 years of experience in the pharmaceutical and healthcare industries in senior roles in the UK, Asia Pacific and Australia. Roger is also a director or chairman on a number of boards carrying out late-stage drug development.

John Martin
Executive Director

John Martin has served on the Board as an Executive Director since early 2009 and was appointed CEO in November 2014.

John has more than 20 years’ experience as a business executive, director and corporate lawyer including roles as CEO and director of ASX-listed and private emerging technology companies, including BTF and Proteome Systems.

He was a corporate and executive partner of Allens specialising in mergers and acquisitions, fundraising and life sciences.

Professor Graham Vesey
Executive Director

Professor Graham Vesy is a co-founder and founding CEO of Regeneus, and has served on the Board since incorporation. He was appointed Chief Scientific Officer in November 2014.

Graham is a successful biotechnology entrepreneur, technology innovator and inventor, and a highly regarded scientist. Graham was a co-founder and Executive Director or the successful biotech start-up, BTF, which was sold to bioMerieux in 2007. He is an Adjunct Professor at Macquarie University.

Barry Sechos
Non-Executive Director

Barry Sechos has served on the Board since 2012 and has more than 20 years’ experience as a director, business executive and corporate lawyer, with particular experience in investment and asset management.

He is an Executive Director of the Sherman Group (an early-stage investor in the Company) and sits on the Board of many Sherman Group companies and investee companies.

Dr Glen Richards
Non-Executive Director

Dr Glen Richards has served on the Board since April 2015. He practised companion animal medicine and surgery in Brisbane, Townsville and London before establishing Greencross Vets in 1994. As Managing Director of Greencross Ltd (ASX: GXL) he created Australia’s largest veterinary healthcare group with more than 120 veterinary practices and 200 pet specialty stores.

He resigned as MD of GXL in December 2014 and continues as a Non-executive Director. Glen is a Director of Smartvet Pty Ltd, a biotech company developing an innovative application of paraciticides for cattle. He is also a Non-executive Director of 1300smiles (ASX: ONT), an aggregator of dental facilities across Australia.

Leo Lee
Non-Executive Director

Leo Lee has served on the Board since December 2017. He is a Senior executive with more than 20 years of experience in pharmaceutical innovation, commercialisation, regulatory and policy.

He has worked in North America, Asia and has lived and worked in Japan the last 12 years. Leo was previously President of Allergan, Japan and former President of Merck Japan.